JP5252459B2 - リボフラノシルピリミジンヌクレオシドの調製 - Google Patents

リボフラノシルピリミジンヌクレオシドの調製 Download PDF

Info

Publication number
JP5252459B2
JP5252459B2 JP2009532372A JP2009532372A JP5252459B2 JP 5252459 B2 JP5252459 B2 JP 5252459B2 JP 2009532372 A JP2009532372 A JP 2009532372A JP 2009532372 A JP2009532372 A JP 2009532372A JP 5252459 B2 JP5252459 B2 JP 5252459B2
Authority
JP
Japan
Prior art keywords
aryl
formula
methyl
fluoro
tetrahydrofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009532372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505954A (ja
JP2010505954A5 (https=
Inventor
スティーブン， ディー． アクスト，
ケシャブ サルマ，
ジャスティン ヴィターレ，
ジャン ジュ，
ブルース ロス，
スグナ ラチャコンダ，
キンウー ジン，
ビョン−クォン チュン，
Original Assignee
ギリアド ファーマセット エルエルシー
エフ． ホフマン ラ−ロシュ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアド ファーマセット エルエルシー, エフ． ホフマン ラ−ロシュ アーゲー filed Critical ギリアド ファーマセット エルエルシー
Publication of JP2010505954A publication Critical patent/JP2010505954A/ja
Publication of JP2010505954A5 publication Critical patent/JP2010505954A5/ja
Application granted granted Critical
Publication of JP5252459B2 publication Critical patent/JP5252459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2009532372A 2006-10-10 2007-10-05 リボフラノシルピリミジンヌクレオシドの調製 Active JP5252459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85096206P 2006-10-10 2006-10-10
US60/850,962 2006-10-10
PCT/US2007/021548 WO2008045419A1 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines

Publications (3)

Publication Number Publication Date
JP2010505954A JP2010505954A (ja) 2010-02-25
JP2010505954A5 JP2010505954A5 (https=) 2013-04-04
JP5252459B2 true JP5252459B2 (ja) 2013-07-31

Family

ID=39111500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009532372A Active JP5252459B2 (ja) 2006-10-10 2007-10-05 リボフラノシルピリミジンヌクレオシドの調製

Country Status (18)

Country Link
US (2) US8912321B2 (https=)
EP (1) EP2084174B1 (https=)
JP (1) JP5252459B2 (https=)
KR (1) KR101057239B1 (https=)
CN (1) CN101600725B (https=)
AU (1) AU2007307057B2 (https=)
BR (1) BRPI0719174A2 (https=)
CA (1) CA2666098C (https=)
DK (1) DK2084174T3 (https=)
ES (1) ES2429290T3 (https=)
GT (1) GT200900080A (https=)
IL (1) IL198086A (https=)
MX (1) MX2009003795A (https=)
PL (1) PL2084174T3 (https=)
PT (1) PT2084174E (https=)
RU (1) RU2421461C2 (https=)
SI (1) SI2084174T1 (https=)
WO (1) WO2008045419A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9098916B2 (en) 2004-11-17 2015-08-04 Thomson Licensing Bit-accurate film grain simulation method based on pre-computed transformed coefficients
US9117261B2 (en) 2004-11-16 2015-08-25 Thomson Licensing Film grain SEI message insertion for bit-accurate simulation in a video system
US9177364B2 (en) 2004-11-16 2015-11-03 Thomson Licensing Film grain simulation method based on pre-computed transform coefficients
US10715834B2 (en) 2007-05-10 2020-07-14 Interdigital Vc Holdings, Inc. Film grain simulation based on pre-computed transform coefficients

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US8492539B2 (en) * 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
AU2009329872B2 (en) * 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
JP5716500B2 (ja) * 2010-06-03 2015-05-13 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類前駆体の製造方法
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
PT2855497T (pt) * 2012-05-29 2016-07-28 Gilead Pharmasset Llc Processo para a preparação de compostos de nucleósidos de 2-desoxi-2-fluoro-2-metil-d-ribofuranosilo
CN103450148B (zh) * 2012-06-04 2018-06-12 浙江九洲药业股份有限公司 一种五元环硫酸酯化合物的合成方法
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
CN103724301A (zh) * 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CN103012386B (zh) * 2012-12-26 2015-04-01 浙江普洛得邦制药有限公司 一种五元环状硫酸酯的制备方法
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
CN104744539A (zh) * 2014-09-19 2015-07-01 上海皓元生物医药科技有限公司 一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的合成方法
CN104327138B (zh) * 2014-10-21 2017-05-10 齐鲁制药有限公司 Psi‑7977中间体化合物的制备方法
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN104610404B (zh) * 2015-01-16 2016-04-06 南通常佑药业科技有限公司 一种呋喃核糖磷酸酯衍生物的制备方法
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CN104829672B (zh) * 2015-05-19 2018-03-13 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN105061535A (zh) * 2015-09-02 2015-11-18 江苏科本医药化学有限公司 一种索非布韦中间体的合成方法
CN106554333B (zh) * 2015-09-29 2018-11-30 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN106608896B (zh) * 2015-10-26 2019-08-27 江苏福瑞康泰药业有限公司 一种药物中间体的合成方法
CN105418547A (zh) * 2015-11-17 2016-03-23 海门慧聚药业有限公司 索非布韦关键中间体的制备
CN105503983B (zh) * 2015-12-17 2019-06-28 江苏阿尔法药业有限公司 索菲布韦中间体及其衍生物的制备方法
CN105566422B (zh) * 2015-12-29 2019-06-25 江苏阿尔法药业有限公司 索菲布韦中间体或其衍生物的制备方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
CN106810515A (zh) * 2017-02-06 2017-06-09 抚州市星辰药业有限公司 一种合成索非布韦的中间体化合物及其合成方法
CN109422789A (zh) * 2017-08-28 2019-03-05 常州制药厂有限公司 一种索非布韦的制备工艺改进方法
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN108675984A (zh) * 2018-06-22 2018-10-19 江苏阿尔法药业有限公司 索非布韦中间体的制备方法
CN111606961A (zh) * 2019-02-26 2020-09-01 顾世海 一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的工艺生产方法
CN111040010A (zh) * 2019-12-23 2020-04-21 上海红蓝医药科技有限公司 一种索非布韦中间体的合成方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850002973A (ko) * 1983-10-03 1985-05-28 구라바야시 이꾸시로 시티딘 유도체의 제조방법
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
WO1999043691A1 (en) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
CA2380644A1 (en) 1999-07-30 2001-02-08 Basf Aktiengesellschaft 2-pyrazolin-5-ones
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
HUE029877T2 (en) * 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
DK1741716T3 (da) * 2004-04-30 2011-11-28 Daiichi Sankyo Co Ltd Fremgangsmåde til fremstilling af pentacyklisk taxan
EP2348029A1 (en) * 2004-07-21 2011-07-27 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
US8492539B2 (en) * 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9117261B2 (en) 2004-11-16 2015-08-25 Thomson Licensing Film grain SEI message insertion for bit-accurate simulation in a video system
US9177364B2 (en) 2004-11-16 2015-11-03 Thomson Licensing Film grain simulation method based on pre-computed transform coefficients
US9098916B2 (en) 2004-11-17 2015-08-04 Thomson Licensing Bit-accurate film grain simulation method based on pre-computed transformed coefficients
US10715834B2 (en) 2007-05-10 2020-07-14 Interdigital Vc Holdings, Inc. Film grain simulation based on pre-computed transform coefficients

Also Published As

Publication number Publication date
BRPI0719174A2 (pt) 2017-06-13
AU2007307057A1 (en) 2008-04-17
KR20090060460A (ko) 2009-06-12
RU2009117396A (ru) 2010-11-20
CA2666098A1 (en) 2008-04-17
US20080139802A1 (en) 2008-06-12
JP2010505954A (ja) 2010-02-25
SI2084174T1 (sl) 2013-10-30
KR101057239B1 (ko) 2011-08-16
RU2421461C2 (ru) 2011-06-20
DK2084174T3 (da) 2013-11-04
EP2084174A1 (en) 2009-08-05
CN101600725B (zh) 2014-11-26
AU2007307057B2 (en) 2011-09-15
WO2008045419A1 (en) 2008-04-17
IL198086A0 (en) 2009-12-24
US8912321B2 (en) 2014-12-16
PT2084174E (pt) 2013-10-08
GT200900080A (es) 2012-04-10
CN101600725A (zh) 2009-12-09
EP2084174B1 (en) 2013-07-31
US20100056770A1 (en) 2010-03-04
IL198086A (en) 2012-03-29
ES2429290T3 (es) 2013-11-14
MX2009003795A (es) 2009-06-18
HK1133889A1 (en) 2010-04-09
PL2084174T3 (pl) 2013-12-31
CA2666098C (en) 2012-09-25

Similar Documents

Publication Publication Date Title
JP5252459B2 (ja) リボフラノシルピリミジンヌクレオシドの調製
JP2010505954A5 (https=)
EP0342203B1 (en) 2',3' dideoxyribofuranoxide derivatives
EP0717748B1 (fr) Composes 2' ou 3'-deoxy- et 2', 3'-dideoxy-beta-l-pentofuranonucleosides, procede de preparation et application therapeutique, notamment anti-virale
EP2855497B1 (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds
JP2010512365A (ja) ４’−アジドシチジン誘導体の製造方法
JP2004538318A (ja) リバビリンの調製法
CN102171195B (zh) 合成地西他滨
US9624258B2 (en) Polymorph of regadenoson
CA2442979C (en) Process for the preparation of 2'-halo-.beta.-l-arabinofuranosyl nucleosides
HK1133889B (en) Preparation of nucleosides ribofuranosyl pyrimidines
CN114456169A (zh) 3′-脱氧-3′,4′-二脱氢核糖核苷类似物及其制备方法
JP2006516249A (ja) ２−デオキシ−ｄ−グルコースの合成方法
JP4691101B2 (ja) １−α−ハロ−２，２−ジフルオロ−２−デオキシ−Ｄ−リボフラノース誘導体及びその製造方法
Huang et al. Synthesis of (±)-cis-1-[2-(Hydroxymethyl)-1, 3-Oxathiolan-5-yl] cytosine and Its (±)-trans Isomer
TW202521548A (zh) 用於製備３－經取代５－胺基－６Ｈ－噻唑并［４，５－ｄ］嘧啶－２，７－二酮化合物之方法
HK1148738A (en) Process for production of ethynylthymidine compound using 5-methyluridine as starting raw material
JPH08134065A (ja) ３’−アミノ−３’−デオキシヌクレオシドの製造方法及びその合成中間体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120928

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130212

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130409

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5252459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160426

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250